Chengdu Zeyan Biotechnology

Chengdu Zeyan Biotechnology is a biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative small molecule drugs for oncology. Established in 2021, the company focuses on targeting the RAS/MAPK signaling pathway to address unmet needs in solid tumors. Its lead candidate, ZY-022, is a highly selective KRAS G12D inhibitor currently in the IND-enabling stage for the treatment of pancreatic, colorectal, and lung cancers. The pipeline also includes inhibitors for SHP2 and SOS1, designed for both monotherapy and combination strategies to overcome drug resistance. Zeyan Bio utilizes a proprietary structure-based drug design platform to optimize its development candidates. The company is led by a team of industry veterans and is supported by prominent venture capital firms including Legend Capital and HighLight Capital.